Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
OncoSil Medical Ltd ( (AU:OSL) ) has issued an announcement.
OncoSil Medical Limited has announced the first commercial use of its OncoSil™ device in the UK for treating unresectable locally advanced pancreatic cancer, marking a significant milestone in its commercial operations. This treatment, performed at Southampton General Hospital, transitions the company from clinical trials to commercial activity in the UK, targeting an addressable market opportunity of $138 million annually. The device is expected to benefit approximately 3,600 eligible patients per year in the UK, reinforcing OncoSil’s commitment to expanding access to innovative cancer treatments globally.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Limited is a global medical device company specializing in Interventional Oncology. The company focuses on improving cancer patient outcomes through the targeted intratumoural placement of Phosphorous-32 Microparticles, alongside chemotherapy. Their primary product, the OncoSil™ device, is designed for treating unresectable locally advanced pancreatic cancer, allowing for a higher radiation dose directly into the tumor while minimizing exposure to surrounding organs. The device has received CE Marking approval and is recognized as a breakthrough device in Europe and the United States, with approval for sale in over 30 countries.
Average Trading Volume: 24,148
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$20.8M
Find detailed analytics on OSL stock on TipRanks’ Stock Analysis page.